【摘要】 目的观察沙美特罗联合丙酸氟替卡松粉吸入对咳嗽变异型哮喘(CVA)的治疗效果及安全性。方法将56例临床诊断为CVA的(5～14)岁患儿先予舒利迭(沙美特罗替卡松粉)吸入(<1月),咳嗽症状消失后改用辅舒酮(丙酸氟替卡松粉)维持治疗,疗程3个月,观察咳嗽消失时间,并分别在治疗前、治疗后1个月、3个月、6个月及12个月测定呼气峰流速值(PEF),观察肺功能情况及出现的不良反应。结果56例CVA患儿除1例失访外,咳嗽症状均于治疗后4周内消失。治疗1个月后PEF值基本达预计值80%以上,与治疗前比较(P<0.01),差别显著。结论沙美特罗联合氟替卡松粉吸入治疗CVA使用方便、疗效肯定、安全、无明显不良反应。更多还原

【Abstract】 Objective: To evaluate the effect of Salmetorol Xinafoate and Fluticasone Propionate powder on cough variant asthma (CVA). Methods: All 56 patients aged from 5~14 years, who have been clinically diagnosed to have CVA, were treated with inhaling Salmetorol Xinafoate and Fluticasone Propionate powder until the symptom of cough disappeared for about 30 days, then inhaling secondly fluticasone propionate powder only until 3 months. The time of disappeared cough was recorded and the level of peak expiratory flow (PEF) was detected before treatment and after 1, 3, 6, 12 treatment months. The pulmonary function and side effect of the drug were observed. Results: 55 cases had got rid from the cough in 4 weeks. The value of PEF in all patients was more available (80%) after one-month treatment than that before treatment and there was a significant difference (P 0.01 ). Except of two cases with hoarseness there were no other side effects to occur. Conclusions: It’s convenient, safe and reliable for the children with CVA to inhale Salmetorol Xinafoate and Fluticasone Propionate power in routine dosage.更多还原